Rheumatology

Roche's 2020 Losses to Biosimilars Were "Worst It Can Get"

February 9th 2021

Biosimilar competition took a big chunk of revenue from Roche's aging blockbusters in 2020, and the company is banking on its newer medicines to drive fresh revenue growth.

Study: Biosimilar Use Varies by Type of Institution and Physician Characteristics

February 8th 2021

By Tony Hagen

Physician specialty and practice setting each play a significant role in whether biosimilars are administered vs originators, according to a large, cross-sectional study.

Celltrion Gains Canadian Nod for Subcutaneous Infliximab

February 5th 2021

By Tony Hagen

Celltrion aims to try a direct marketing approach in Canada to streamline sales of its subcutaneous form of Remsima.

Amgen Profits Get a Ride on Biosimilar Growth

February 4th 2021

By Tony Hagen

Amgen described how a double-edged biosimilars sword has worked for and against the company's profit margin.

Celltrion Executive Discusses Adalimumab Biosimilar Candidate

February 3rd 2021

HoUng Kim, PhD, head of the Medical and Marketing Division at Celltrion Healthcare, discusses how the company’s adalimumab biosimilar candidate, CT-P17, stands out from the competition.

FDA Accepts Bio-Thera's BLA for Bevacizumab Biosimilar

January 29th 2021

By Tony Hagen

Guangzhou, China-based Bio-Thera has filed a biologics license application (BLA) with the FDA for the approval of bevacizumab biosimilar candidate BAT1706.

Vizient Predicts 7.5% Humira Price Increase Before Biosimilars Arrive

January 28th 2021

By Tony Hagen

In its annual drug price guide, Vizient predicts that US annual adalimumab (Humira) revenues could reach $24 billion before biosimilars enter the marketplace.

Nurses Can Counter Nocebo Effect in Biosimilar Switching

January 27th 2021

By Tony Hagen

The study of originator infliximab and SB2 used nurses as the first point of contact when educating patients, relying partly on patient trust in these health care professionals.

China Pulls Out Stops for Biosimilar Development

January 25th 2021

By Tony Hagen

It took Henlius years to get a rituximab biosimilar approved in China. Now, that process could be cut in half, owing to significant regulatory reforms.

Investigators Weigh Differences in Biosimilar Quality Reporting

January 23rd 2021

By Deana Ferreri, PhD

Consistency of reporting quality attributes for biosimilars may differ, complicating the job of getting a full picture of biosimilarity.